Sign in Subscribe
COVID-19

New FDA Policy Shifts COVID-19 Vaccine Approach for Healthier Adults and Children

Strategic Insights

— 2 min read

The US Food and Drug Administration (FDA) has unveiled a major policy shift in how COVID-19 vaccines are approved for annual use in the US. According to the new framework, healthy younger adults and children will no longer be routinely approved for annual COVID-19 shots. Instead, the FDA will require companies to conduct large, lengthy studies before approving tweaked vaccines for healthier individuals. This approach still allows for annual vaccinations to be available for 100 million to 200 million adults, mainly those aged 65 and older, as well as those with at least one health problem that puts them at higher risk.

Key Takeaways:

  • The new FDA policy shift marks a departure from the previous approach of approving annual updates to COVID-19 vaccines based on manufacturers' evidence of continued immune protection.
  • The framework, published in the New England Journal of Medicine, suggests that annual vaccinations may still be available for 100 million to 200 million adults, primarily those aged 65 and older, as well as those with at least one health problem that puts them at higher risk.
  • The FDA's new guidance urges companies to conduct large, lengthy studies to determine the effectiveness of tweaked vaccines in healthier individuals.
  • Comments from vaccine expert Dr. Paul Offit suggest that the new policy may make vaccines less insurable and less available, particularly for those who do not clearly fall into one of the designated high-risk groups.
  • Offit also stated that the new framework may usurp the role of the Centers for Disease Control and Prevention (CDC) advisory panel, which had been set to debate the question of whether everyone still benefits from yearly COVID vaccination.
  • The FDA framework appears to reflect concerns about the US being the most aggressive in recommending COVID boosters, as compared with European countries.

Statistics:

  • The new FDA framework suggests that annual vaccinations may still be available for up to 200 million adults.
  • The FDA approval process will now require companies to conduct large, lengthy studies to determine the effectiveness of tweaked vaccines in healthier individuals.
  • CDC studies have shown that booster doses offer protection against mild to moderate illness for four to six months after the shot even in healthy people.

Sources:

  • New England Journal of Medicine, "Framework for Evaluating COVID-19 Vaccines: Streamlining the Process While Maintaining Safety and Effectiveness," published online, exact date not specified.
  • Department of Health and Human Services, attributed as the source of the FDA framework.
  • Children's Hospital of Philadelphia, via Dr. Paul Offit, vaccine expert, quoted in the article.

Read more